EP Patent

EP2373621A2 — Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof

Assigned to Molecular Insight Pharmaceuticals Inc · Expires 2011-10-12 · 15y expired

What this patent protects

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radi…

USPTO Abstract

Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

Drugs covered by this patent

Patent Metadata

Patent number
EP2373621A2
Jurisdiction
EP
Classification
Expires
2011-10-12
Drug substance claim
No
Drug product claim
No
Assignee
Molecular Insight Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.